Ipamorelin lab tests

Seven checks before you trust a Ipamorelin certificate

The same seven questions decide whether a certificate of analysis means anything, whichever compound it describes. Six are about the document; the seventh is about what no document can tell you.

1. An independent, batch-matched COA. The certificate must name the batch or lot in your hands, and must come from a laboratory the vendor neither owns nor pays. A specimen certificate from an earlier lot proves nothing about the vial you were sent.
2. HPLC purity, read against a known band. A purity figure is only informative against the distribution for that compound. "Above 98%" is not a claim — the useful question is whether the result sits inside the range the rest of the market reports. How to read HPLC and mass-spec results.
3. Mass-spectrometry identity. HPLC says how much of the sample is one thing; it does not say which thing. Only a mass-spec result establishes identity, and it is the only check that separates compounds a few daltons apart. Contamination is not hypothetical: research-grade custom peptides from two independent commercial suppliers were found to carry contaminating peptides at roughly 1% by weight, enough to produce false-positive results in immunology assays (Clinical and Vaccine Immunology, 2008 — a study of HIV vaccine peptide libraries rather than of any compound on this site).
4. Net content, measured rather than assumed. Purity and quantity are different questions: a vial can be 99.7% pure and still contain two thirds of the labelled mass. Why 10 mg isn't 10 mg.
5. Endotoxin (LAL) on the batch. An absent endotoxin line means the batch was not tested — not that it passed. Endotoxin testing and LAL interpretation.
6. Who ran the test, and what they left off. A laboratory with a record on this compound, named on the certificate, with a verification route back to it. Testing laboratories we track · Red flags in a certificate of analysis.
7. What no test on the vial can establish. A perfect certificate confirms that a vendor sold the correct molecule at the stated quantity. It says nothing about efficacy, dosing, or long-term safety.

Want a vial tested yourself? How to send a peptide for independent HPLC testing.

What ipamorelin testing has to rule out

Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH₂: CAS 170851-70-4 (PubChem CID 9831659), formula C₃₈H₄₉N₉O₅, molecular weight 711.9 g/mol, monoisotopic mass 711.3857 ([M+H]⁺ 712.3929), developer code NNC 26-0161. It carries no Trp-Trp core — the motif shared by GHRP-2, GHRP-6 and hexarelin — using Aib and D-2-naphthylalanine instead, so it is a genuinely different molecule rather than a one-residue variant, and it sits 106 to 175 daltons below every compound it is sold beside. Any mass spectrometer, including a low-resolution one, separates them, which makes an ipamorelin certificate with a purity figure and no identity result a choice rather than a technical limitation.

Because identity is nearly free to confirm, the realistic risks are underfill and non-peptide bulking: salts, residual water and bulking agents that a purity percentage will not reveal. FDA's compounding review called the free base "not well-characterized from the physical and chemical characterization perspective", with impurities, aggregates and endotoxin data missing. The Pharmacy Compounding Advisory Committee voted on the free base and the acetate as separate substances in October 2024, and it is ipamorelin acetate that sits on FDA's Category 2 list (added 29 September 2023), so a listing that names neither form has not specified the substance it is selling.

Confirming the molecule does not confirm the selectivity claim sold with it. Ipamorelin's lack of a cortisol and prolactin response was demonstrated in conscious swine by Raun et al. (1998), at doses more than 200-fold above its own GH ED₅₀; the familiar comparison with GHRP-2 and GHRP-6 mixes animal data for one compound with human data for the others.

One citation circulating on product pages is misattributed. A paper titled "Ipamorelin for postoperative ileus: results of phase II/III trials" is attributed to PMID 11600700, which is actually "The role of acetylation in rDNA transcription", a 2001 molecular biology paper in Nucleic Acids Research. No phase II/III ipamorelin publication exists, and a page citing one was not fact-checked.

• Mass spectrometry at 711.3857 monoisotopic, or 712.3929 as the [M+H]⁺ ion; a nominal-mass result is sufficient here.
• A mass at 817.4275 (GHRP-2), 872.4446 (GHRP-6) or 886.4602 (hexarelin) is a different secretagogue — gaps of 106.04, 161.06 and 175.07 Da.
• Net peptide content or amino acid analysis, reported separately from purity — the check that matches this compound's actual failure mode.
• An LAL endotoxin result on the batch; FDA named missing endotoxin data specifically.
• The form — free base or acetate — named on the label and the certificate.